the promise of luspatercept for the treatment of lower-risk mds
Published 1 year ago • 117 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
1:19
the promise of precision medicine in mds
-
7:01
hematopathology-red-cells-ida_final.mp4
-
19:00
case study: sequencing therapy in es-sclc in special patient populations
-
11:00
what do the guidelines suggest for prophylaxis, and how do we implement?
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
1:52
investigating luspatercept utilization patterns in lower-risk mds
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
4:12
novel therapies in low-risk mds
-
0:56
luspatercept for mds-associated anemia
-
7:05
state-of-the-art treatment regimens for lr-mds
-
2:43
novel therapies in the future of mds treatment
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:16
state of the art: mds
-
2:04
state-of-the-art treatment for hr-mds